Skip to content
FoodEdge
News

Korean GLP-1 sell-out: EUR 6.8M of stock, or EUR 0.9M?

Hanmi’s half-price EPPE ran out six days into prescribing. The reported stock value and Hanmi’s own batch size point to very different launch volumes, and that gap is the diligence lesson.

For Investors
Five white medicine cartons in grey, purple, teal, orange and red, in strengths from 2 mg to 10 mg, with matching autoinjector pens in front.
EPPE cartons and autoinjectors in five dose strengths. Photo: Hanmi Pharmaceutical, press release image.

Hanmi Pharmaceutical’s EPPE (efpeglenatide), the first GLP-1 obesity drug developed in Korea, ran out of launch stock six days after clinics began prescribing it, Korean press reports. Its starter price is about half of Mounjaro’s, in a market where patients pay in full, so the price signal is clear. The volume signal is weaker than the headline. An industry estimate values the stock at EUR 6.8M (KRW 10bn), while Hanmi described the batch as enough for about 10,000 patients, which at the starter price comes to about EUR 0.9M. For nutrition companies sizing Korea’s GLP-1 user base, that gap matters more than the sell-out.

At a glance

  • EUR 88(KRW 129,800) for EPPE’s first four weeks at supply price, against about EUR 189 (KRW 278,000) for Mounjaro (Sidae Ilbo)
  • 6 daysfrom first prescriptions to sold-out launch stock on 4 November (Sidae Ilbo)
  • EUR 6.8M(KRW 10bn) launch stock at supply price, an industry estimate (Sidae Ilbo)
  • 10,000patients: Hanmi’s own description of the first batch (TheBell)

Korean press reports of 22 October to 20 November 2026; the KRW 10bn figure comes from unnamed industry and medical sources. EUR at the ECB reference rate of 20 November 2026 (KRW 1,472.04). Checked 21 November 2026.

Korea’s drug regulator approved EPPE on 7 October, Hanmi said. The company claims a mean weight loss of 9.75% at 40 weeks in an interim topline readout of a Phase 3 trial in 448 Korean patients, and makes the drug at its own Pyeongtaek bio plant. Shipments began on 22 October and prescribing at some clinics was due to start on 29 October, a Hanmi spokesperson told Kyeonggi Ilbo.

Sidae Ilbo reports, citing industry and medical sources, that the launch stock, about KRW 10bn (EUR 6.8M) at supply price, was gone by 4 November. At that pace it estimates about KRW 20bn (EUR 13.6M) for the first four weeks, while noting that the figure is at supply price and rivals’ figures are distribution values. Three days earlier a Hanmi spokesperson told the same paper that the first stock was mostly used up as soon as it was supplied.

Obesity drugs are not reimbursed in Korea. EPPE’s first four weeks cost KRW 129,800 (EUR 88) at supply price, against about KRW 278,000 (EUR 189) for Mounjaro and about KRW 220,000 (EUR 149) for Wegovy. In the first half of 2026 Mounjaro sold KRW 744.4bn (EUR 506M) in Korea and Wegovy KRW 217bn (EUR 147M), IQVIA data cited by Sidae show. A Hanmi spokesperson told Sidae the company aims to grow EPPE to KRW 200bn (EUR 136M) a year in the medium to long term.

The batch size comes from TheBell, where a Hanmi spokesperson declined to give a volume but called it enough for about 10,000 people. TheBell also reports that Pyeongtaek’s second plant, built for efpeglenatide, fell to 0% utilisation in 2022 after Sanofi returned the rights, and that Hanmi plans 70% this year and 90% in 2027. Nationwide supply to clinics and pharmacies is planned from January 2027.

FoodEdge view: price moved demand, and the batch size decides what it proves

Our reading is that the price signal is real and the volume signal is unmeasured. A batch Hanmi itself sized at about 10,000 patients ran out in six days, which shows that self-pay patients in Korea move on price. At the starter price, 10,000 courses come to about EUR 0.9M, so the EUR 6.8M estimate needs many more packs or higher doses. The firmer signal is industrial: an idle Pyeongtaek line now has its own product.

The due diligence question: how many four-week packs shipped, at which doses, and how many starters refilled at full-dose prices?

Weighing a food biotech or nutrition deal? Independent technical due diligence, before you sign.

How we checked

  1. Sources: Hanmi approval release, 7 Oct 2026; Sidae Ilbo, 20 Nov 2026 and 17 Nov 2026; TheBell, 22 Oct 2026; Kyeonggi Ilbo, 29 Oct 2026. All read in Korean; translations are FoodEdge’s.
  2. Snapshot: 21 November 2026; EUR at the ECB reference rate of 20 November 2026 (KRW 1,472.04).
  3. Key assumption: EUR 0.9M is 10,000 patients times one four-week starter course at KRW 129,800. The KRW 10bn estimate equals about 77,000 starter courses, about 7.7 per patient, so it holds only if the batch covered several months per patient or higher doses at higher prices.
  4. Main limit: Hanmi has published no sales figure, batch size in doses or price list. The price and stock figures come from Korean press citing unnamed industry and medical sources, and the trial result is a company claim.

AI tools supported source research and drafting during the editorial process.

DiscussionOpenClose

More to explore

All publications